Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy
Journal of Clinical Oncology · 01.07.2026 · 44 (19) · 1767-1773
DOI: 10.1200/jco-25-03051 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.07.2026. Verfasst von Lara Stepan und 23 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Myers Squibb, Seattle, WA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
We report correlative circulating tumor DNA (ctDNA) analyses from TRANSFORM (ClinicalTrials.gov identifier: NCT03575351 ) evaluating lisocabtagene maraleucel (liso-cel) versus standard of care (salvage immunochemotherapy, high-dose chemotherapy, autologous stem cell transplantation [ASCT]) in second-line large B-cell lymphoma (LBCL). ctDNA association with efficacy was investigated at predefined time points (random assignment, day 43, day 64, and day 126 [3 months after liso-cel, approximately 2 months after ASCT]) for 136 patients using ultrasensitive PhasED-Seq. ctDNA clearance (measurable residual disease [MRD] neg ) predicted longer event-free survival (EFS) at all time points in both arms, with significantly more liso-cel–treated patients achieving MRD neg . Liso-cel demonstrated superior outcomes versus ASCT, including longer EFS, progression-free survival (PFS), and duration of response among patients in complete response (CR) and MRD neg . ctDNA re-emergence in patients with CR after ASCT confirmed its potential in predicting relapse. MRD neg remained significantly associated with EFS after adjusting for positron emission tomography (PET) response, while interaction testing revealed a significant interaction between PET status and treatment arm for EFS. Liso-cel achieved deeper, more durable molecular clearance by ctDNA, consistent with superior EFS and PFS versus ASCT for second-line LBCL treatment. ctDNA-MRD provided prognostic value beyond PET, supporting its role as a complementary biomarker for treatment response and relapse prediction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Bristol Myers Squibb, Seattle, WA.
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
- Bristol Myers Squibb, Cambridge, MA.
- Bristol Myers Squibb, Boudry, Switzerland.
- University of Colorado Cancer Center, Aurora, CO.
- Northside Hospital Cancer Institute, Atlanta, GA.
ORCID-Profile: Jeremy S Abramson, Manali Kamdar, Scott R Solomon, Patrick B Johnston, Bertram Glass, Pim Mutsaers, Stephan Mielke, Mazyar Shadman, Koji Izutsu, Veronika Bachanova, Sami Ibrahimi, David M Kurtz, Ash A Alizadeh, Leanne Peiser
Zitieren
APA
Stepan, L., Ansari, S., Abramson, J. S., Okal, A., Dell'Aringa, J., Thompson, E. G., Crotta, A., Chow, V. A., Kamdar, M., Solomon, S. R., Johnston, P. B., Glass, B., Mutsaers, P., Arnason, J., Mielke, S., Shadman, M., Hernandez-Ilizaliturri, F., Izutsu, K., Bachanova, V., …, & Peiser, L. (2026). Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy. Journal of Clinical Oncology, 44(19), 1767-1773. https://doi.org/10.1200/jco-25-03051
Vancouver
Stepan L, Ansari S, Abramson JS, Okal A, Dell'Aringa J, Thompson EG, et al. Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy. Journal of Clinical Oncology. 2026;44(19):1767-1773. doi:10.1200/jco-25-03051
BibTeX
@article{Stepan2026,
author = {Stepan, Lara and Ansari, Sahar and Abramson, Jeremy S and Okal, Abood and Dell'Aringa, Justine and Thompson, Ethan G and Crotta, Alessandro and Chow, Victor A and Kamdar, Manali and Solomon, Scott R and Johnston, Patrick B and Glass, Bertram and Mutsaers, Pim and Arnason, Jon and Mielke, Stephan and Shadman, Mazyar and Hernandez-Ilizaliturri, Francisco and Izutsu, Koji and Bachanova, Veronika and Ibrahimi, Sami and Chabon, Jacob J and Kurtz, David M and Alizadeh, Ash A and Peiser, Leanne},
title = {Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {19},
pages = {1767--1773},
doi = {10.1200/jco-25-03051}
}
EUVIMED